Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.49 |
| ▸ | HRH2 | P25021 | 15/20 | 0.48 |
| ▸ | HRH1 | P35367 | 15/20 | 0.48 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095921 | 0.90 | HRH3 (0.56) | HRH3HRH2HRH1KCNA5SMN1; SMN2 | |
| SCHEMBL2954545 | 0.87 | KCNH2 (0.48) | HRH3HRH2HRH1 | |
| SCHEMBL6989099 | 0.86 | KCNH2 (0.51) | HRH3HRH2HRH1SMN1; SMN2 | |
| SCHEMBL5965822 | 0.85 | HRH3 (0.47) | HRH3HRH2HRH1SMN1; SMN2 | |
| SCHEMBL7028521 | 0.83 | EGLN2 (0.40) | HRH3HRH2HRH1KCNA5 | |
| SCHEMBL7033710 | 0.82 | HRH2 (0.38) | HRH3HRH2HRH1 | |
| SCHEMBL6621505 | 0.81 | KCNA5 (0.48) | HRH3HRH2HRH1KCNA5SMN1; SMN2 | |
| SCHEMBL6989155 | 0.80 | HRH3 (0.48) | HRH3HRH2HRH1 | |
| SCHEMBL7030745 | 0.80 | SIGMAR1 (0.56) | HRH3HRH2HRH1 | |
| SCHEMBL7034662 | 0.80 | KCNH2 (0.42) | HRH3HRH2HRH1KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | HRH3 402/4885HRH2 229/4885HRH1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.